共 50 条
HDAC6 and Ovarian Cancer
被引:27
|作者:
Haakenson, Joshua
[1
]
Zhang, Xiaohong
[1
,2
]
机构:
[1] Univ S Florida, Morsani Coll Med, Dept Pathol & Cell Biol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA
关键词:
HDAC6;
ovarian cancer;
cancer-related signaling pathways;
inhibitors;
cell stress response;
motility;
oncogenesis;
histone deacetylase;
HISTONE DEACETYLASE 6;
REGULATES AGGRESOME FORMATION;
2 CATALYTIC DOMAINS;
CELL-MIGRATION;
MICROTUBULE ACETYLATION;
GLUCOCORTICOID-RECEPTOR;
STRESS GRANULES;
PROTEIN;
TUBULIN;
INHIBITORS;
D O I:
10.3390/ijms14059514
中图分类号:
Q5 [生物化学];
Q7 [分子生物学];
学科分类号:
071010 ;
081704 ;
摘要:
The special class IIb histone deacetylase, HDAC6, plays a prominent role in many cellular processes related to cancer, including oncogenesis, the cell stress response, motility, and myriad signaling pathways. Many of the lessons learned from other cancers can be applied to ovarian cancer as well. HDAC6 interacts with diverse proteins such as HSP90, cortactin, tubulin, dynein, p300, Bax, and GRK2 in both the nucleus and cytoplasm to carry out these cancerous functions. Not all pro-cancer interactions of HDAC6 involve deacetylation. The idea of using HDAC6 as a target for cancer treatment continues to expand in recent years, and more potent and specific HDAC6 inhibitors are required to effectively down-regulate the tumor-prone cell signaling pathways responsible for ovarian cancer.
引用
收藏
页码:9514 / 9535
页数:22
相关论文